show help

Moisi DD

Author page

This page provides a summary of the entries in Polbase associated with this author.

The publication history graph presents the number of publications in Polbase by this author over time.

The polymerase chart indicates which polymerases this author has published on.

Polbase automatically discovers many polymerase papers as they are published. Some relevant papers are not included because the algorithm is designed to reduce background. Please contribute to polbase by adding your missing DNA polymerase papers.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Missing references?

Publications:

Title Authors Year Journal
The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites. Moisi DD 2013 The Journal of antimicrobial chemotherapy
Basis for the Early and Preferential Selection of the E138K Substitution in HIV-1 Reverse Transcriptase with Etravirine. Moisi DD 2013 Antimicrobial agents and chemotherapy
Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. Moisi DD 2011 The Journal of antimicrobial chemotherapy
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. Moisi DD 2011 PloS one
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. Moisi DD 2011 Journal of medical virology
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Moisi DD 2011 Antimicrobial agents and chemotherapy
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. Moisi DD 2009 Journal of virology
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. Moisi DD 2009 The Journal of infectious diseases
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Moisi DD 2009 Antimicrobial agents and chemotherapy
Transmission networks of drug resistance acquired in primary/early stage HIV infection. Moisi DD 2008 AIDS (London, England)
Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. Moisi DD 2008 AIDS research and human retroviruses
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Moisi DD 2007 Antimicrobial agents and chemotherapy
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. Moisi DD 2006 AIDS (London, England)
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs. Moisi DD 2005 Journal of the International AIDS Society
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Moisi DD 2004 Antimicrobial agents and chemotherapy
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. Moisi DD 2004 Journal of acquired immune deficiency syndromes
Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Moisi DD 2004 Antiviral chemistry & chemotherapy
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Moisi DD 2004 Antimicrobial agents and chemotherapy
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. Moisi DD 2004 AIDS (London, England)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Moisi DD 2003 AIDS (London, England)
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Moisi DD 2003 Antimicrobial agents and chemotherapy
Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Moisi DD 2002 Antiviral therapy
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Moisi DD 2002 Antimicrobial agents and chemotherapy
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. Moisi DD 2002 Journal of virology
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1. Moisi DD 2002 Antimicrobial agents and chemotherapy
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Moisi DD 2002 Antiviral research

Using Polbase tables:

Sorting:

Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).

Filtering:

It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.